Dihydroberberine Composition for Brown Adipose Tissue Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pharmacological and nutritional strategies are inadequate for effectively and safely recruiting or activating brown adipose tissues (BAT) in humans, which is crucial for addressing metabolic disorders such as obesity and improving insulin sensitivity.

Innovation Solution

Administration of dihydroberberine or its pharmaceutically acceptable derivatives to induce brown/brite-typical gene expression, increase transcription of PRDM16 and UCP1 via AMPK activation and PGC-1α recruitment, promoting BAT recruitment and activation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional pharmacological or nutritional strategies are used to recruit or activate BAT, then the approach is safe, but the effectiveness is insufficient

Engineering Contradiction:

ImprovesafetyVSAvoideffectiveness

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the chemical structure parameter by using dihydroberberine instead of traditional berberine, and modifies the dosage parameters to achieve superior effectiveness while maintaining safety. The compound structure and administration dosage are optimized to enhance BAT recruitment and activation effectiveness.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If berberine is used to promote BAT thermogenesis, then metabolic benefits are achieved, but intestinal absorption rate is limited

Engineering Contradiction:

Improvemetabolic benefitsVSAvoidintestinal absorption rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the chemical structure parameter by hydrogenating berberine to form dihydroberberine, which fundamentally alters the absorption characteristics. This structural modification increases intestinal absorption rate five-fold while maintaining the metabolic benefits through AMPK activation and PGC-1α recruitment.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If berberine is used to increase transcription of PRDM16 and UCP1, then BAT activation is promoted, but the effect requires intestinal bacteria breakdown

Engineering Contradiction:

ImproveBAT activationVSAvoiddependency on intestinal bacteria

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent extracts the dependency on intestinal bacteria by using dihydroberberine, which does not require bacterial breakdown. This removes the variable of intestinal microbiota from the mechanism of action, allowing direct absorption and action of the compound to activate BAT through AMPK and PGC-1α pathways.

Inventive Principle:

Principle #2Taking out (Extraction)

4Productivity

If dihydroberberine is administered to induce brown/brite-typical gene expression, then BAT recruitment is enhanced, but the mechanism is complex involving AMPK and PGC-1α

Engineering Contradiction:

ImproveBAT recruitmentVSAvoidmechanism complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent identifies and targets the preliminary action points in the signaling pathway - AMPK activation and PGC-1α recruitment - as the critical control points for BAT recruitment. By focusing on these upstream regulators, the complex downstream effects are streamlined into a manageable mechanism that can be therapeutically exploited.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enhances BAT thermogenesis, energy expenditure, reduces body weight, and improves metabolic profiles by increasing UCP1 and PGC-1α expression, thereby improving glucose metabolism and insulin sensitivity.

Implementation Method 1

increasing the transcription of PRDM16 and UCP1 via AMPK activation and PGC-1α recruitment

Methodology Applied

Scientific EffectAMPK activation:

Implementation Method 2

BAT is specialized to combust energy by a process termed non-shivering thermogenesis mediated by mitochondrial UCP1

Methodology Applied

Scientific EffectThermogenesis:

Implementation Method 3

BAT and WAT are morphologically and functionally different tissues, and their developmental patterns are quite distinct. BAT is histologically distinct from WAT, it composes of multilocular lipid droplets and large numbers of mitochondria that contain mitochondrial uncoupling protein-1 (UCP1)

Methodology Applied

Scientific EffectUCP1-mediated energy dissipation:

Data Source

PatentUS20250375430A1Use of dihydroberberine to promote recruitment and activation of brown adipose tissues

Publication Date: 2025.12.11 NANJING NUTRABUILDING BIO TECH CO LTD

AI summary

The present invention provides novel methods for promoting recruitment and activation of brown adipose tissues (BAT) or arousing browning of white adipose tissues (WAT) in a mammal, comprising administration to the mammal a composition comprising an effective amount of dihydroberberine or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof. The present invention also provides a composition comprising an effective amount of dihydroberberine or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof, for promoting recruitment and activation of brown adipose tissues (BAT) or arousing browning of white adipose tissues (WAT) in a mammal.